An expert discusses how proactive referral, multidisciplinary coordination, and early identification can optimize outcomes for patients with muscle-invasive bladder cancer, especially those with ...
Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC. According to the authors, “ADVC001 is a novel PSMA ...
In determining the best treatment, urologist Arpeet Shah, MD, stresses the importance of thorough diagnostics. In this video, recorded at the 2025 LUGPA Annual Meeting, Arpeet Shah, MD, a urologist ...
TRAVERSE trial showed no increase in MACE with testosterone therapy, improving sexual function and depression symptoms without affecting diabetes or prostate cancer outcomes. T4DM trial found a 13% ...
The gemcitabine intravesical system offers localized chemotherapy delivery, providing a promising option for patients who have failed previous treatments. Successful implementation of new therapies ...
The BioProtect Balloon Spacer significantly preserves bowel, urinary, and sexual quality of life in prostate cancer patients undergoing radiation therapy over four years. The study showed ...
Looking forward, Meeks said he sees nadofaragene firadenovec as a promising addition to the NMIBC treatment landscape. In this interview, conducted at the 2025 LUGPA Annual Meeting, Joshua J. Meeks, ...
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025. Host Amy Pearlman, MD, discusses premature ejaculation with Brian L. Steixner, MD, a ...
Hear from 5 experts as they recap some of the top data from this year's ESMO Congress. Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates ...
Louise K. Kostos, MBBS, FRACP, PhD candidate, outlines initial findings from the phase 1/2 AlphaBet trial. Data from the phase 1/2 AlphaBet trial (NCT05383079) were presented at the 2025 European ...
The KEYNOTE-905 trial showed significant survival benefits with enfortumab vedotin and pembrolizumab in muscle-invasive bladder cancer, suggesting a new standard for cisplatin-ineligible patients. The ...
177Lu-PSMA-617 addition to ADT and ARPI significantly improved rPFS in PSMA-positive mHSPC patients, with consistent benefits across subgroups. The PSMAddition trial showed a trend toward improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback